Interní Med. 2014; 16(4): 156-158

Non-corpuscular hyperviscosity syndrome in clinical practice

MUDr.Tomáš Pika, Ph.D.1, MUDr.Zdenka Kosatíková1, Mgr.Jarmila Juráňová2, MUDr.Petr Mlčák3
1 III. interní klinika &ndash, nefrologická, revmatologická, endokrinologická, LF UP a FN Olomouc
2 Hemato-onkologická klinika, FN Olomouc
3 Oční klinika, FN Olomouc

Hyperviscosity syndrome (HVS) from non-corpuscular cause is a clinical and laboratory syndrome due to increased blood viscosity, mostly

caused by excessive levels or modified physical and chemical characteristics of serum immunoglobulins. Clinical features of HVS are typical

in patients with monoclonal gammopathies – multiple myeloma and Waldenström´s macroglobulinemia. They can be, however, found in

other conditions such as cryoglobulinemia or systemic connective tissue disorders. The presence of clinical manifestation accompanied

with decreased organ perfusion, and laboratory confirmation of increased viscosity are the major aspects supporting plasmapheresis

as supportive treatment modality in these patients.

Keywords: non-corpuscular viscosity, viscosity, hyperviscosity syndrome, plasmapheresis

Published: June 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pika T, Kosatíková Z, Juráňová J, Mlčák P. Non-corpuscular hyperviscosity syndrome in clinical practice. Interní Med. 2014;16(4):156-158.
Download citation

References

  1. Adam Z. Waldeströmova makroglobulinemie. In: Adam Z, Krejčí M, Vorlíček J, et al. Hematologie - přehled maligních hematologických nemocí. Grada 2008, 264.
  2. Machálková K, Radocha J, Maisnar V. Hyperviskózní syndrom u pacientů s mnohočetným myelomem. Klin Biochem Metab 2011; 19: 93-95.
  3. Ballestri M, Ferrari F, Magistroni R, et al. Plasma exchange in acute and chronic hyperviscosity syndrome: a rheological approach and guidelines study. Ann Ist Super Sanita 2007; 43: 171-175. Go to PubMed...
  4. Stone MJ. Waldenström´s mocroglobulinemia: hyperviscosity syndrome and cryoglobulinemia. Clin Lymph Myeloma 2009; 9: 97-99. Go to original source... Go to PubMed...
  5. Scofield RH, Tardibono G, Ogden SB, Harley JB, Reichlin M, Kurien BT. Rheumatoid hyperviscosity: analysis of patient with intermediate complexes that block other autoantibodies and rewiew of the literature. Semin Arthritis Rheum 1998; 27: 382-391. Go to original source... Go to PubMed...
  6. Čermáková Z, Gottwaldová J. Kryoglobulinémie a její rizika při laboratorním vyšetřování. Klin Biochem Metab 2009; 17: 79-80.
  7. Minařík J, Pika T, Bačovský J, Ščudla V. Kryoglobulinemická vaskulitida u nemocného s mnohočetným myelomem. Interní Med 2012; 14: 478-480.
  8. Menke MN, Feke GT, McMeel JW, Treon SP. Opthalmologic techniques to assess the severity of hyperviscosity syndrome and the effect of plasmapheresis in patients with Waldenström´s macroglobulinemia. Clin Lymph Myeloma 2009; 9: 100-103. Go to original source... Go to PubMed...
  9. Blum W, Porcu P. Therapeutic apheresis in hyperleukocytosis and hyperviscosity syndrome. Semin Thromb Hemost 2007; 33: 350-354. Go to original source... Go to PubMed...
  10. Ghobrial IM, Fonseca R, Greipp PR, et al. Initial immunoglobulin M ´flare´ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia. Cancer 2004; 101: 2593-2598. Go to original source... Go to PubMed...
  11. Adam Z, Pour L, Krejčí M, et al. Poškození ledvin při mnohočetném myelomu a dalších monoklonálních gamapatiích. Vnitř Lék 2008; 54: 847-861. Go to PubMed...
  12. Clark WF, Stewart AK, Rock GA, et al. Plasma exchange when myeloma presents as acute renal failure: A randomized, controlled trial. Ann Intern Med 2005; 143: 777-784. Go to original source... Go to PubMed...
  13. Orság J, Pika T, Kosatíková Z, et al. Hemodialýza s použitím, ,high cut-off" membrán u mnohočetného myelomu - první zkušenosti. Klin Biochem Metab 2013; 21: 88-92.




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.